HCG

Current Scenario & Financial Performance - Q2 FY27 Consolidated Revenue grew 16% YoY to ₹7,318 million, supported by a 9% volume growth and a 7% increase in ARPP. - Q2 EBITDA stood at ₹1,425 million (up 17% YoY) with an EBITDA margin of 19.7%, impacted by a ₹60 million wage revision under the Karnataka Wage Act. - H1 FY27 Revenue reached ₹14,100 million (+15% YoY), while Adjusted EBITDA rose 18% YoY to ₹2,740 million, and Adjusted PAT grew 30% YoY to ₹287 million. Management Guidance & Outlook - Reaffirmed guidance of mid-teens organic revenue growth and high-teens to ~20% EBITDA growth. - North Bengaluru hospital losses narrowed to ₹61 million in Q2; on track to achieve monthly EBITDA breakeven by Q4 FY27. - The recent trade margin cap on oncology drugs is estimated to have a mid-to-high single-digit percentage annualized impact on EBITDA, with no material impact expected starting FY28. - Gujarat cluster growth expected to normalize to mid-teens by Q4 FY27 following deliberate rationalization of low-margin institutional business. Capex, Debt & Growth Drivers - Incurred ₹1,279 million capex in H1 FY27; operationalized 146 beds in H1 (including 25 beds in Q2 across Kenya, Kolkata, and Nagpur). - Repaid ₹1,700 million in debt during H1 FY27, with net debt (excluding leases) standing at ₹5,751 million as of September 30, 2026. - Growth driven by high-complexity oncology procedures, a 37% YoY surge in robotic surgeries, and expanding non-institutional payor mix to 69% of total revenue.

- Audio recording of the Earnings Call held on November 06, 2026, is available on the company website. - The call covered Unaudited Financial Results for the quarter and half-year ended September 30, 2026.

- HealthCare Global Enterprises Limited announced that its Nomination and Remuneration Committee approved the grant of 70,000 Employee Stock Options under the HCG ESOS 2026 on November 05, 2026. - Each option converts into one equity share of face value ₹10 at an exercise price of ₹495 per share. - The vesting period ranges between 1 to 7 years from the grant date, with an exercise period of up to 10 years.

- Q2 FY27 Revenue increased 16% YoY to ₹7,318 Mn, supported by 9% volume growth and 7% ARPP improvement. - Adjusted EBITDA grew 17% YoY to ₹1,425 Mn with margins reaching 19.7%. - Added 146 operational beds in H1 FY27 and expanded advanced oncology therapies and robotic surgeries.

Q2 FY27 Consolidated Revenue ₹731.8Cr vs ₹632.1Cr (▲16% YoY) EBITDA ₹142.5Cr vs ₹121.5Cr (▲17% YoY) PAT ₹19.2Cr vs ₹21.2Cr (▼9% YoY) EBITDA Margin 19.7% vs 19.2% (▲51bps)

Q2 FY27 Consolidated Revenue ₹730.16Cr vs ₹645.16Cr (▲13.2% YoY) EBITDA ₹122.80Cr vs ₹123.62Cr (▼0.7% YoY) PAT ₹9.25Cr vs ₹20.66Cr (▼55.2% YoY) EBITDA Margin 16.8% vs 19.2% (▼234bps)

Concall Schedule Concall Date: November 06, 2026 Concall Time: 12:30 PM IST